<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100771">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01830959</url>
  </required_header>
  <id_info>
    <org_study_id>REFS-1</org_study_id>
    <secondary_id>WIRB Pr #:  20130426</secondary_id>
    <nct_id>NCT01830959</nct_id>
  </id_info>
  <brief_title>Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)</brief_title>
  <acronym>REFS</acronym>
  <official_title>Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Albany Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary sarcoidosis patients with fibrosis often develop recurrent episodes of bronchitis.
      These can lead to worsening of disease for both the short and long term.

      Roflumilast has been shown to reduce the number of acute bronchitis episodes in patients
      with COPD.

      Drugs similar to Roflumilast have been shown to help sarcoidosis. The current study is to
      determine if Roflumilast will reduce number of episodes of bronchitis and help fibrotic
      sarcoidosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a multicenter, double blind, placebo controlled study. Patients would be
      randomized 1:1 to receive either roflumilast 500 mcg per day or placebo added to their
      current treatment regimen for twelve months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reduction in number of episodes of acute exacerbation</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Collect number of episodes of exacerbtion in one year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in FVC</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in FVC over time of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure QOL using Sarcoidosis health question, fatigue assessment score, SGRQ, SF-36 Leicester cough questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>recard adverse events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>Roflumilast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Roflumilast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
    <description>Roflumilast</description>
    <arm_group_label>Roflumilast</arm_group_label>
    <other_name>Roflumilast</other_name>
    <other_name>Daliresp</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo one a day</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with sarcoidosis as defined by the American Thoracic Society criteria

          2. Patients with an FEV1/FVC ratio of less than 80%

          3. Patients with fibrosis on chest x-ray and/or high resolution CT scan.

          4. Patients have had at least two exacerbations of their sarcoidosis in the prior year.
             An exacerbation is defined as an acute event requiring increase of prednisone with or
             without use of antibiotics.

          5. Patients must be on a stable dose of corticosteroids and other agents for their
             sarcoidosis at least 4 weeks prior to first visit.

          6. For patients on prednisone alone, the dose has to be the equivalent of 5 mg
             prednisone a day. For those on other immunosuppressants, they can be on any dose of
             prednisone.

          7. Patients must be between ages of 18 and 70 years of age.

          8. Willing to take prednisone at increased dosage for exacerbations of their
             sarcoidosis.

          9. Patients must be able to provide written informed consent to participate in the
             study.

        Exclusion Criteria:

          1. Patients with known hypersensitivity to theophylline or pentoxifylline will not be
             eligible. Patients with dose dependent nausea from these drugs may still participate
             in the trial.

          2. Patients will not be able to take theophylline or pentoxifylline during the time of
             the study. They will be allowed to take drugs for sarcoidosis including prednisone,
             methotrexate, azathioprine, leflunomide, hydroxychloroquine, thalidomide, infliximab,
             adalimumab, and rituximab.

          3. Patients with serum creatinine of greater than 3 mg/dL

          4. Patients with moderate or severe liver disease as defined Child Pugh class 3 or 4.

          5. Patients with unstable cardiac disease

          6. Patients with non cutaneous malignancy treated in the past two years.

          7. Patients unable to complete the questionnaires and six minute walks detailed in the
             study.Women of child bearing potential unable to use adequate birth control as
             determined by the investigator.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert P Baughman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert P Baughman, MD</last_name>
    <phone>513-584-5225</phone>
    <email>bob.baughman@uc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rebecca Ingledue</last_name>
    <phone>513-584-6252</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert P Baughman, MD</last_name>
      <phone>513-584-5225</phone>
      <email>bob.baughman@uc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Ingledue</last_name>
      <phone>513-584-6252</phone>
    </contact_backup>
    <investigator>
      <last_name>Robert P Baughman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 1, 2014</lastchanged_date>
  <firstreceived_date>April 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Robert P Baughman</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Sarcoidosis, fibrosis, bronchiectasis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
